Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Gammadelta Therapeutics Limited has 3 pending office actions in Biotechnology & Pharmaceuticals. The profile identifies 3 distinct examiners and 3 distinct art units. STEPHENS, AMELIA CAROLE is the busiest examiner, with 1 pending matter. The pending work is therefore distributed across three examination assignments, with the busiest examiner responsible for one matter.
This distribution makes docket separation important. Counsel should track each action against its examiner and art unit, while coordinating claim terminology and disclosure positions across the biotechnology and pharmaceutical portfolio. A response strategy that works in one assignment may not address the issues in another. The record supports centralized review of overall claim scope, paired with separate substantive responses to each pending action.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (33%) |
| §103 only | 1 (33%) |
| Double-patenting + other | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STEPHENS, AMELIA CAROLE | 1 | 75.0% | +50.0% |
| MIANO, JOSEPH PAUL | 1 | 35.7% | +63.4% |
| ALSOMAIRY, SARAH ABDOALATIF | 1 | 57.4% | +30.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18044195 | IMMUNOTHERAPY COMPOSITION | STEPHENS, AMELIA CAROLE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18044195 | IMMUNOTHERAPY COMPOSITION | STEPHENS, AMELIA CAROLE | — |
| 17998766 | METHODS FOR ISOLATING GAMMA DELTA T CELLS | MIANO, JOSEPH PAUL | — |
| 17904890 | EX VIVO GAMMA DELTA T CELL POPULATIONS | ALSOMAIRY, SARAH ABDOALATIF | — |
| Art Unit | Apps |
|---|---|
| 1645 | 1 |
| 1631 | 1 |
| 1646 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18044195 | IMMUNOTHERAPY COMPOSITION | STEPHENS, AMELIA CAROLE | 1645 | §101§102§103§112 | Non-Final OA | — | Pending | Mar 06, 2023 |
| 17998766 | METHODS FOR ISOLATING GAMMA DELTA T CELLS | MIANO, JOSEPH PAUL | 1631 | §103Other | Final Rejection | — | Pending | Nov 14, 2022 |
| 17904890 | EX VIVO GAMMA DELTA T CELL POPULATIONS | ALSOMAIRY, SARAH ABDOALATIF | 1646 | §112DP | Non-Final OA | — | Pending | Aug 24, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGammadelta Therapeutics Limited has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Amelia Carole Stephens has the most, with 1 of Gammadelta Therapeutics Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
